CN1858240A - 预测血管紧张素ii受体拮抗剂类降压药作用的方法及应用 - Google Patents
预测血管紧张素ii受体拮抗剂类降压药作用的方法及应用 Download PDFInfo
- Publication number
- CN1858240A CN1858240A CNA2005100116795A CN200510011679A CN1858240A CN 1858240 A CN1858240 A CN 1858240A CN A2005100116795 A CNA2005100116795 A CN A2005100116795A CN 200510011679 A CN200510011679 A CN 200510011679A CN 1858240 A CN1858240 A CN 1858240A
- Authority
- CN
- China
- Prior art keywords
- receptor
- angiotensin
- gene
- test kit
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 47
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 title abstract description 7
- 239000000018 receptor agonist Substances 0.000 title description 9
- 229940044601 receptor agonist Drugs 0.000 title description 9
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims abstract description 75
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 72
- 239000003814 drug Substances 0.000 claims abstract description 47
- 239000000556 agonist Substances 0.000 claims abstract description 43
- 230000001077 hypotensive effect Effects 0.000 claims abstract description 43
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 40
- 230000000694 effects Effects 0.000 claims abstract description 32
- 238000001514 detection method Methods 0.000 claims abstract description 15
- 108050000824 Angiotensin II receptor Proteins 0.000 claims description 63
- 102000008873 Angiotensin II receptor Human genes 0.000 claims description 63
- 239000000523 sample Substances 0.000 claims description 62
- 238000006243 chemical reaction Methods 0.000 claims description 35
- 238000012360 testing method Methods 0.000 claims description 31
- 210000004369 blood Anatomy 0.000 claims description 30
- 239000008280 blood Substances 0.000 claims description 30
- 230000037353 metabolic pathway Effects 0.000 claims description 29
- 229940079593 drug Drugs 0.000 claims description 23
- 102000004190 Enzymes Human genes 0.000 claims description 21
- 108090000790 Enzymes Proteins 0.000 claims description 21
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims description 21
- 239000012472 biological sample Substances 0.000 claims description 20
- 239000002947 C09CA04 - Irbesartan Substances 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 230000000857 drug effect Effects 0.000 claims description 18
- 229960002198 irbesartan Drugs 0.000 claims description 18
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims description 18
- 239000005557 antagonist Substances 0.000 claims description 16
- 108010075604 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase Proteins 0.000 claims description 13
- 108090000854 Oxidoreductases Proteins 0.000 claims description 13
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 12
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims description 11
- 108091008146 restriction endonucleases Proteins 0.000 claims description 11
- 239000002083 C09CA01 - Losartan Substances 0.000 claims description 10
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- 229960004563 eprosartan Drugs 0.000 claims description 10
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims description 10
- 229960004773 losartan Drugs 0.000 claims description 10
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims description 10
- 102200088705 rs1801394 Human genes 0.000 claims description 10
- 229960000651 tasosartan Drugs 0.000 claims description 10
- ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 claims description 10
- 229960005187 telmisartan Drugs 0.000 claims description 10
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims description 9
- 239000002081 C09CA05 - Tasosartan Substances 0.000 claims description 9
- 230000003750 conditioning effect Effects 0.000 claims description 9
- 230000029087 digestion Effects 0.000 claims description 9
- 229960004699 valsartan Drugs 0.000 claims description 9
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 9
- 239000002053 C09CA06 - Candesartan Substances 0.000 claims description 8
- 229960000932 candesartan Drugs 0.000 claims description 8
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims description 8
- 239000005480 Olmesartan Substances 0.000 claims description 7
- 238000006911 enzymatic reaction Methods 0.000 claims description 7
- 229960005117 olmesartan Drugs 0.000 claims description 7
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 6
- 239000002207 metabolite Substances 0.000 claims description 6
- 210000002200 mouth mucosa Anatomy 0.000 claims description 6
- 210000003296 saliva Anatomy 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 210000002700 urine Anatomy 0.000 claims description 6
- 210000000601 blood cell Anatomy 0.000 claims description 5
- 230000002503 metabolic effect Effects 0.000 claims description 5
- 239000003340 retarding agent Substances 0.000 claims description 5
- 238000013461 design Methods 0.000 claims description 4
- 239000013067 intermediate product Substances 0.000 claims description 4
- 238000012827 research and development Methods 0.000 claims description 4
- 238000011144 upstream manufacturing Methods 0.000 claims description 4
- 239000005515 coenzyme Substances 0.000 claims description 3
- 238000012163 sequencing technique Methods 0.000 claims description 3
- 208000007530 Essential hypertension Diseases 0.000 abstract description 9
- 210000000056 organ Anatomy 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 108020004707 nucleic acids Proteins 0.000 abstract description 3
- 102000039446 nucleic acids Human genes 0.000 abstract description 3
- 150000007523 nucleic acids Chemical class 0.000 abstract description 3
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 abstract description 2
- 206010020772 Hypertension Diseases 0.000 description 26
- 239000007788 liquid Substances 0.000 description 26
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 19
- 238000011282 treatment Methods 0.000 description 17
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 16
- 102100029684 Methylenetetrahydrofolate reductase Human genes 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 101000587058 Homo sapiens Methylenetetrahydrofolate reductase Proteins 0.000 description 12
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 description 12
- 208000024172 Cardiovascular disease Diseases 0.000 description 11
- 230000036772 blood pressure Effects 0.000 description 11
- 230000001631 hypertensive effect Effects 0.000 description 11
- 230000003321 amplification Effects 0.000 description 10
- 239000002220 antihypertensive agent Substances 0.000 description 10
- 229940127088 antihypertensive drug Drugs 0.000 description 10
- 235000019152 folic acid Nutrition 0.000 description 10
- 239000011724 folic acid Substances 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 9
- 230000003276 anti-hypertensive effect Effects 0.000 description 9
- 229960000304 folic acid Drugs 0.000 description 9
- 230000004060 metabolic process Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 239000005541 ACE inhibitor Substances 0.000 description 8
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 8
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 8
- 101150082137 Mtrr gene Proteins 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 8
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 8
- ZNOVTXRBGFNYRX-ABLWVSNPSA-N levomefolic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-ABLWVSNPSA-N 0.000 description 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 229930182817 methionine Natural products 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 102000011848 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase Human genes 0.000 description 6
- 101150059573 AGTR1 gene Proteins 0.000 description 6
- 102100024614 Methionine synthase reductase Human genes 0.000 description 6
- 102000004316 Oxidoreductases Human genes 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 102200088972 rs1801133 Human genes 0.000 description 6
- 101001116314 Homo sapiens Methionine synthase reductase Proteins 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 206010042957 Systolic hypertension Diseases 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 238000013016 damping Methods 0.000 description 5
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 230000002974 pharmacogenomic effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 4
- 206010008190 Cerebrovascular accident Diseases 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 239000005864 Sulphur Substances 0.000 description 4
- VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000006555 catalytic reaction Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 235000007635 levomefolic acid Nutrition 0.000 description 4
- 239000011578 levomefolic acid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000002547 new drug Substances 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 101800000733 Angiotensin-2 Proteins 0.000 description 3
- 102400000345 Angiotensin-2 Human genes 0.000 description 3
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 3
- 125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 3
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 3
- 229950006323 angiotensin ii Drugs 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000035487 diastolic blood pressure Effects 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- 235000019158 vitamin B6 Nutrition 0.000 description 3
- 239000011726 vitamin B6 Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 101800004490 Endothelin-1 Proteins 0.000 description 2
- 108010057573 Flavoproteins Proteins 0.000 description 2
- 102000003983 Flavoproteins Human genes 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 2
- 101150107184 MS gene Proteins 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 101150025887 PRCP gene Proteins 0.000 description 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 108010076723 adducin Proteins 0.000 description 2
- 229960001570 ademetionine Drugs 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000001779 embryotoxic effect Effects 0.000 description 2
- 231100000238 embryotoxicity Toxicity 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 101150044508 key gene Proteins 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 230000009245 menopause Effects 0.000 description 2
- 210000004914 menses Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 230000008816 organ damage Effects 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- TYEYBOSBBBHJIV-UHFFFAOYSA-N 2-oxobutanoic acid Chemical compound CCC(=O)C(O)=O TYEYBOSBBBHJIV-UHFFFAOYSA-N 0.000 description 1
- 101150100998 Ace gene Proteins 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 239000002051 C09CA08 - Olmesartan medoxomil Substances 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- YPWSLBHSMIKTPR-UHFFFAOYSA-N Cystathionine Natural products OC(=O)C(N)CCSSCC(N)C(O)=O YPWSLBHSMIKTPR-UHFFFAOYSA-N 0.000 description 1
- 102100034976 Cystathionine beta-synthase Human genes 0.000 description 1
- 108010073644 Cystathionine beta-synthase Proteins 0.000 description 1
- 108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 description 1
- 102000002269 Cytochrome P-450 CYP2C9 Human genes 0.000 description 1
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 1
- ILRYLPWNYFXEMH-UHFFFAOYSA-N D-cystathionine Natural products OC(=O)C(N)CCSCC(N)C(O)=O ILRYLPWNYFXEMH-UHFFFAOYSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102100033902 Endothelin-1 Human genes 0.000 description 1
- 102000010911 Enzyme Precursors Human genes 0.000 description 1
- 108010062466 Enzyme Precursors Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 206010070538 Gestational hypertension Diseases 0.000 description 1
- 201000005624 HELLP Syndrome Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 101100514680 Homo sapiens MTHFR gene Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- -1 Kang Deshatan) Chemical compound 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ILRYLPWNYFXEMH-WHFBIAKZSA-N L-cystathionine Chemical compound [O-]C(=O)[C@@H]([NH3+])CCSC[C@H]([NH3+])C([O-])=O ILRYLPWNYFXEMH-WHFBIAKZSA-N 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 108010030837 Methylenetetrahydrofolate Reductase (NADPH2) Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- UQGKUQLKSCSZGY-UHFFFAOYSA-N Olmesartan medoxomil Chemical compound C=1C=C(C=2C(=CC=CC=2)C2=NNN=N2)C=CC=1CN1C(CCC)=NC(C(C)(C)O)=C1C(=O)OCC=1OC(=O)OC=1C UQGKUQLKSCSZGY-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- 208000005347 Pregnancy-Induced Hypertension Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 108010042865 aquacobalamin reductase Proteins 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000011863 diuretic therapy Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000009342 intercropping Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 229940101564 micardis Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960001199 olmesartan medoxomil Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000012495 positive regulation of renal sodium excretion Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 208000036335 preeclampsia/eclampsia 1 Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 102200154562 rs397515451 Human genes 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229940048102 triphosphoric acid Drugs 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000000283 vasomotion Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Variable/Genotype | N | Mean±S.D. | Unadjusted | Adjusted* | ||||
β | S.E. | P | β | S.E. | P | |||
Female |
SBPDBP | CCCTTTCCCTTT | 1772335317723353 | 18.6±20.819.1±17.525.7±19.66.4±8.97.2±7.810.0±9.4 | Ref0.57.1Ref0.83.6 | -1.93.1-0.81.4 | -0.7790.022-0.3640.013 | Ref-0.35.9Ref0.02.5 | -1.82.7-0.81.3 | -0.8890.029-0.9890.050 |
Variable/Genotype | N | Mean±S.D. | Unadjusted | Adjusted* | |||||
β | S.E. | P | β | S.E. | P | ||||
Mild Hypertension | |||||||||
SBPDBP | AAAG+GGAAAG+GG | 182138182138 | 11.3±16.814.9±16.34.8±8.26.8±8.1 | Ref3.6Ref2.0 | -1.9-0.9 | -0.051-0.033 | Ref3.9Ref2.0 | -1.8-0.9 | -0.033-0.023 |
Claims (23)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005100116795A CN1858240B (zh) | 2005-04-30 | 2005-04-30 | 预测血管紧张素ii受体拮抗剂类降压药作用的方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005100116795A CN1858240B (zh) | 2005-04-30 | 2005-04-30 | 预测血管紧张素ii受体拮抗剂类降压药作用的方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1858240A true CN1858240A (zh) | 2006-11-08 |
CN1858240B CN1858240B (zh) | 2011-06-15 |
Family
ID=37297198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005100116795A Active CN1858240B (zh) | 2005-04-30 | 2005-04-30 | 预测血管紧张素ii受体拮抗剂类降压药作用的方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1858240B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109182510A (zh) * | 2018-11-06 | 2019-01-11 | 宁波艾捷康宁生物科技有限公司 | 高血压个体化药物治疗基因型检测snp位点和配套试剂盒 |
CN109295216A (zh) * | 2018-11-06 | 2019-02-01 | 宁波艾捷康宁生物科技有限公司 | 预测高血压个体化药物药效的snp位点和检测试剂盒 |
CN112210591A (zh) * | 2020-11-16 | 2021-01-12 | 合肥中科支众医学检验有限公司 | 一种检测人mthfr基因c677t位点多态性的方法 |
CN114088692A (zh) * | 2021-11-13 | 2022-02-25 | 普十生物科技(北京)有限公司 | 一种hcy检测用还原试剂、试剂盒及其使用方法 |
CN117482053A (zh) * | 2023-11-02 | 2024-02-02 | 山东京卫制药有限公司 | 一种替米沙坦的制粒方法及其固体制剂的制备方法 |
-
2005
- 2005-04-30 CN CN2005100116795A patent/CN1858240B/zh active Active
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109182510A (zh) * | 2018-11-06 | 2019-01-11 | 宁波艾捷康宁生物科技有限公司 | 高血压个体化药物治疗基因型检测snp位点和配套试剂盒 |
CN109295216A (zh) * | 2018-11-06 | 2019-02-01 | 宁波艾捷康宁生物科技有限公司 | 预测高血压个体化药物药效的snp位点和检测试剂盒 |
CN112210591A (zh) * | 2020-11-16 | 2021-01-12 | 合肥中科支众医学检验有限公司 | 一种检测人mthfr基因c677t位点多态性的方法 |
CN114088692A (zh) * | 2021-11-13 | 2022-02-25 | 普十生物科技(北京)有限公司 | 一种hcy检测用还原试剂、试剂盒及其使用方法 |
CN117482053A (zh) * | 2023-11-02 | 2024-02-02 | 山东京卫制药有限公司 | 一种替米沙坦的制粒方法及其固体制剂的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1858240B (zh) | 2011-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11021751B2 (en) | Disease risk factors and methods of use | |
AU2016204678A1 (en) | Method of identifying disease risk factors | |
CN1926247A (zh) | 检测strp例如脆性x染色体综合征 | |
CN109082464B (zh) | 一种检测高血压药物代谢相关基因的引物组和试剂盒 | |
CN1858240A (zh) | 预测血管紧张素ii受体拮抗剂类降压药作用的方法及应用 | |
CN101063677A (zh) | 一种预测妊娠不良结局发生风险的试剂盒 | |
CN1898394A (zh) | 检测高原肺水肿易感性的方法 | |
CN1982471A (zh) | 多态性位点基因型预测血管紧张素转换酶抑制剂类药物作用效果的用途、方法和试剂盒 | |
CN101029336A (zh) | 预测5-羟色胺再摄取抑制剂类药物作用效果的试剂盒 | |
CN101029337A (zh) | 多态性位点基因型预测5-羟色胺再摄取抑制剂类药物作用效果的用途和方法 | |
CN1891822A (zh) | 具有特定单核苷酸多态性的th基因及其检测方法和用途 | |
CN1827776A (zh) | 一种预测钙拮抗剂药物药效的方法及其应用 | |
CN1858243A (zh) | 一种预测血管紧张素ii受体拮抗剂类降压药药物作用的方法及其应用 | |
CN1217008C (zh) | 一种预测acei类降压药药效的方法 | |
CN101063166A (zh) | 预测血管紧张素转换酶抑制剂类药物作用效果的试剂盒 | |
CN1858241A (zh) | 预测血管紧张素ii受体拮抗剂类降压药作用的方法及应用 | |
Basak et al. | Association of angiotensinogen T174M and M235T gene variants with development of hypertension in Turkish subjects of Trakya region | |
JP6755518B2 (ja) | 血液障害の予後判断方法 | |
CN1442487A (zh) | 犬尿氨酸水解酶多态性及其诊断用途 | |
CN1858242A (zh) | 一种预测血管紧张素ii受体拮抗剂类降压药药物作用的方法及其应用 | |
CN1699595A (zh) | 检测与人类遗传性耳聋相关的wfs1基因突变的方法 | |
CN101063678A (zh) | 一种预测妊娠不良结局发生风险的方法 | |
WO2012096680A1 (en) | Disease risk factors and methods of use | |
CN100338228C (zh) | 一种预测2型糖尿病易感性的试剂 | |
Böttiger et al. | Mutations in exons 2 and 3 of the FOLR1 gene in demented and non-demented elderly subjects |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: ANHUI BIOLOGICAL MEDICAL INST.; APPLICANT Free format text: FORMER OWNER: ANHUI BIOLOGICAL MEDICAL INST. Effective date: 20080815 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20080815 Address after: 153, Medical University Of Anhui, 81 Mei Shan Road, Anhui, Hefei Province, China: 230032 Applicant after: Anhui Biological Medical Institute Co-applicant after: SHENZHEN AUSA PHARMED Co.,Ltd. Address before: 153, Medical University Of Anhui, 81 Mei Shan Road, Anhui, Hefei Province, China: 230032 Applicant before: Anhui Biological Medical Institute |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHENZHEN AOSA MEDICINE CO., LTD.;ANHUI BIOLOGICAL Free format text: FORMER OWNER: SHENZHEN AOSA MEDICINE CO., LTD.;ANHUI BIOLOGICAL MEDICAL INSTITUTE Effective date: 20120307 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20120307 Address after: 153, box 81, Medical University Of Anhui, 230032 Mei Shan Road, Anhui, Hefei Co-patentee after: SHENZHEN AUSA PHARMED Co.,Ltd. Patentee after: Anhui Biological Medical Institute Co-patentee after: Shenzhen Osa Pharmaceutical Co.,Ltd. Address before: 230032 Medical University Of Anhui, 81 Mei Shan Road, Anhui, Hefei 153 Co-patentee before: SHENZHEN AUSA PHARMED Co.,Ltd. Patentee before: Anhui Biological Medical Institute |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Method for predicting angiotonin II receptor agonist hypotensor function and use Effective date of registration: 20130523 Granted publication date: 20110615 Pledgee: China Everbright Bank Shenzhen Bagualing branch Pledgor: Anhui Biological Medical Institute|SHENZHEN AUSA PHARMED Co.,Ltd.|Shenzhen Osa Pharmaceutical Co.,Ltd. Registration number: 2013990000304 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20160705 Granted publication date: 20110615 Pledgee: China Everbright Bank, Limited by Share Ltd, Shenzhen, Bagualing branch Pledgor: Anhui Biological Medical Institute|SHENZHEN AUSA PHARMED Co.,Ltd.|Shenzhen Osa Pharmaceutical Co.,Ltd. Registration number: 2013990000304 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PM01 | Change of the registration of the contract for pledge of patent right |
Change date: 20160705 Registration number: 2013990000304 Pledgee after: China Everbright Bank, Limited by Share Ltd, Shenzhen, Bagualing branch Pledgee before: China Everbright Bank Shenzhen Bagualing branch |
|
CP02 | Change in the address of a patent holder |
Address after: 92 mailbox, Medical University Of Anhui, Mei Shan Road, Anhui, Hefei, 230032 Co-patentee after: SHENZHEN AUSA PHARMED Co.,Ltd. Patentee after: Anhui Biological Medical Institute Co-patentee after: Shenzhen Osa Pharmaceutical Co.,Ltd. Address before: 153, box 81, Medical University Of Anhui, 230032 Mei Shan Road, Anhui, Hefei Co-patentee before: SHENZHEN AUSA PHARMED Co.,Ltd. Patentee before: Anhui Biological Medical Institute Co-patentee before: Shenzhen Osa Pharmaceutical Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230516 Address after: 518057, 1st and 2nd floors of Building 2, Phase III of the Biological Incubator, No. 16, Gaoxin Middle Road, Nanshan District, Shenzhen, Guangdong Province; East side of the first floor and 2nd and 3rd floors of Building 3 Patentee after: SHENZHEN AUSA PHARMACEUTICAL Co.,Ltd. Patentee after: SHENZHEN AUSA PHARMED Co.,Ltd. Patentee after: Shenzhen Osa Pharmaceutical Co.,Ltd. Patentee after: Anhui Biological Medical Institute Address before: 230032 box 92, Anhui Medical University, Meishan Road, Hefei City, Anhui Province Patentee before: Anhui Biological Medical Institute Patentee before: SHENZHEN AUSA PHARMED Co.,Ltd. Patentee before: Shenzhen Osa Pharmaceutical Co.,Ltd. |